triglicérido de butirato

Condiciones de salud que triglicérido de butirato puede ayudar a apoyar.

• DislocaciónCientífico

  Clinical studies of butyrate supplementation, including tributyrin-based products, have documented reductions in abdominal pain and GI discomfort. The 2024 ButyraGen tributyrin pilot study reported only minor GI-related discomfort (<10% of participants). Broader butyrate RCTs confirm pain and bloating benefits in IBS and IBD settings. Evidence specifically for tributyrin form remains preliminary.

• Acidez EstomacalCientífico

  A clinical study of ButyraGen (a tributyrin-containing supplement) reported a 9.29% higher improvement in anxiety rates versus placebo. Mechanistically, butyrate modulates the gut-brain axis by reducing neuroinflammation and influencing cortisol and neurotransmitter pathways. The evidence is preliminary—most human data involve small studies and the tributyrin-specific anxiolytic RCT literature is very thin.

• Contaminación ElectromagnéticaCientífico

  Butyrate (including tributyrin-delivered) modulates immune regulatory pathways relevant to autoimmune disease, notably inducing regulatory T cells (Tregs) and reducing pro-inflammatory cytokines via HDAC inhibition. Animal data show sodium butyrate reduces autoimmune hepatitis development. Disrupted intestinal barrier (leaky gut), which butyrate addresses, is linked to autoimmune conditions. Human clinical evidence specifically targeting autoimmune disease with tributyrin is absent.

• Fatiga SuprarrenalCientífico

  Butyrate plays a significant role in glucose homeostasis and energy metabolism, with supporting evidence from human clinical studies. A Frontiers in Nutrition semi-systematic review (2025) identified multiple clinical trials reporting effects of elevated butyrate production on glucose and insulin markers. An RCT of sodium butyrate in obesity found reductions in blood sugar alongside weight and BMI. Tributyrin's effect on glucose in humans is inferred primarily from animal data and sodium butyrate human trials.

• ApendicitisCientífico

  Tributyrin and its released butyrate suppress inflammatory cytokine production through HDAC inhibition and free-fatty-acid receptor (FFAR) activation. A 2024 study using human visceral adipose tissue showed tributyrin significantly reduced LPS-induced inflammatory cytokines and chemokines. Animal models further confirm tributyrin attenuates adipose tissue inflammation via GPR109A signaling. Human clinical evidence remains largely indirect, via butyrate class as a whole.

• Estrógeno (bajo)Científico

  Tributyrin has direct evidence in experimental colitis models, showing antioxidative and immunomodulatory effects, and reduced colonic mucosal lesions and inflammation when given orally or as an enema. Butyrate enemas were evaluated in human ulcerative colitis trials from 1992 onward with positive but mixed outcomes. Animal models consistently support tributyrin's protection against DSS-induced colitis through barrier repair and cytokine suppression.

• Ojos (rojos o con picazón)Científico

  Oral butyrate has been evaluated in Crohn's disease in small human trials. A PubMed-indexed study administered 4 g/day enteric-coated butyrate to 13 patients with mild-to-moderate ileocolonic Crohn's disease for 8 weeks with colonoscopic evaluation. A 2025 randomized IBD study included 60 Crohn's disease patients alongside UC patients receiving oral butyrate adjunct. Evidence is limited and mixed; tributyrin-specific Crohn's trials do not yet exist.

• Trastorno por Déficit de AtenciónCientífico

  Tributyrin is currently under investigation in a registered pilot RCT as add-on to antidepressant medication in MDD patients, reflecting growing mechanistic and preclinical evidence for butyrate's antidepressant potential via the gut-brain axis. A ButyraGen (tributyrin-containing) clinical study reported a twofold greater likelihood of improvement in depression symptoms in participants without GI disease. Preclinical models of depression consistently show butyrate's antidepressant-like effects. Clinical evidence in humans specifically for depression remains preliminary.

• Leche materna (secar)Científico

  Tributyrin supplementation modulates gut microbiome composition, enriching beneficial bacteria while increasing luminal butyrate. A 2025 in vitro SHIME study using CoreBiome tributyrin showed enrichment of saccharolytic bacterial groups and metabolic shifts in the colonic environment. A 2024 human pilot study (ButyraGen, n=24) confirmed tolerability and SCFA-related microbiome changes. Tributyrin's pharmacokinetic advantage over sodium butyrate—resisting gastric acid and releasing butyrate via colonic lipases—supports its colonic microbiome effects.

• Senos (aumentar tamaño)Científico

  Butyrate is a key mediator of gut-brain axis signaling, acting via vagal afferent pathways, enteroendocrine cells, BDNF upregulation, and neuroinflammation suppression. Tributyrin, as a colonic butyrate delivery vehicle, is now being specifically investigated in a human RCT for its effects on the microbiota-gut-brain axis in depression. The gut-brain connection is the mechanistic framework underpinning tributyrin's neurological research.

• Moretones (prevención)Científico

  Tributyrin prevented body weight gain and reduced adipose tissue inflammation in obese high-fat-diet mice. A sodium butyrate RCT in humans with obesity showed reductions in weight and BMI over 8 weeks. However, the Frontiers in Pharmacology (2021) review concluded no RCT has confirmed an anti-obesity effect of butyrate specifically, and evidence in humans remains limited and inconsistent.

• PulgasCientífico

  Butyrate supplementation has demonstrated symptomatic benefit in IBS across small clinical trials, reducing abdominal pain, urgency, and bloating. A 2025 RCT of calcium butyrate in pediatric IBS (n=51) showed treatment success in 73% vs. 3.8% placebo. A referenced tributyrin-containing product (ButyraGen) trial also noted belly pain reduction. Most IBS evidence uses butyrate salts; tributyrin-specific human IBS RCTs are very limited.

• FlotadoresCientífico

  Butyrate supplementation, including tributyrin, has been evaluated as an adjunct in IBD. Multiple human RCTs using oral butyrate show reductions in inflammatory markers (fecal calprotectin, CRP) and disease activity scores in UC and Crohn's disease. Results are mixed—a pediatric multicenter RCT showed no benefit while a unicentric pediatric RCT showed significant remission advantage. Tributyrin specifically has animal-model support for colitis; direct human IBD tributyrin RCTs are still emerging.

• Olor de piesCientífico

  Animal studies show tributyrin prevents high-fat-diet-induced insulin resistance via GPR109A signaling, and improves glucose metabolism and insulin responsiveness in obese mice. Human evidence is based on butyrate-class trials, including one RCT showing improved metabolic parameters with sodium butyrate in obese subjects. Tributyrin-specific human insulin sensitivity RCTs have not been published.

• Vesícula Biliar (perezosa o extirpada)Científico

  Butyrate is the primary energy source for colonocytes and upregulates tight-junction proteins (claudin-1, occludin, ZO-1) that maintain intestinal barrier integrity. Tributyrin supplementation in antibiotic-treated mice increased tight-junction protein expression and reduced inflammatory mediators. The 2025 in vitro CoreBiome tributyrin study demonstrated a protective effect on intestinal barrier function in Caco-2/THP1 co-cultures. Human RCT data specifically for tributyrin and intestinal permeability are limited.

• GingivitisCientífico

  Butyrate addresses multiple components of metabolic syndrome, including adipose tissue inflammation, glucose dysregulation, and dyslipidemia. A human RCT in patients with liver steatosis and metabolic syndrome using a calcium butyrate formula showed improved fatty liver index and lipid parameters. A sodium butyrate study at 4 g/day for 4 weeks failed to show benefit in metabolic syndrome patients, illustrating inconsistent results. Tributyrin animal data show adipose inflammation reduction and improved insulin responsiveness.

Sistemas corporales que triglicérido de butirato puede ayudar a apoyar.

• No hay sistemas corporales disponibles.